Filtros de búsqueda

Lista de obras de Andrew D Zelenetz

18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.

scientific article published on 04 March 2013

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

artículo científico publicado en 2001

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

artículo científico publicado en 2011

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

artículo científico publicado en 2010

A Phase I Study of Ibrutinib in Combination with R-ICE in Patients with Relapsed or Primary Refractory DLBCL.

artículo científico publicado en 2018

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

artículo científico publicado en 2008

A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.

artículo científico publicado en 2014

A novel gene STORP (STOmatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22.

artículo científico publicado en 2000

A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients

artículo científico publicado en 2013

A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma ⬇️

scientific article published on 21 September 2020

A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.

artículo científico publicado en 2013

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

article

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

artículo científico publicado en 2019

Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.

artículo científico publicado en 2003

Acute Lymphoblastic Leukemia, Version 2.2015.

artículo científico publicado en 2015

Acute lymphoblastic leukemia

scientific article published on 01 July 2012

Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease*

scientific article published on 01 June 2004

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

artículo científico publicado en 2003

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

scientific article published on 01 August 2020

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

artículo científico publicado en 2013

An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma

artículo científico publicado en 2010

Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

artículo científico publicado en 2015

Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine

scientific article published on 01 March 2007

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

artículo científico publicado en 2020

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy

artículo científico publicado en 2020

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

artículo científico publicado en 2005

Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma.

artículo científico publicado en 2013

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: a NLCS and CIBMTR Analysis.

artículo científico publicado en 2017

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

artículo científico publicado en 2006

Automated matching and segmentation of lymphoma on serial CT examinations

artículo científico publicado en 2007

Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma

artículo científico publicado en 1995

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

artículo científico publicado en 2016

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

artículo científico publicado en 2005

Central nervous system involvement in T-cell lymphoma: A single center experience

scientific article published on 04 April 2016

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

artículo científico publicado en 2015

Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era

scientific article published on 30 July 2020

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

artículo científico publicado en 2005

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma

scholarly article by Anita Kumar et al published April 2019 in Haematologica

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

artículo científico publicado en 2016

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

scientific article published on 23 July 2018

Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol

artículo científico publicado en 2001

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database

artículo científico publicado en 2012

Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network

artículo científico publicado en 2014

Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network

artículo científico publicado en 2008

Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy

artículo científico publicado en 2000

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

artículo científico publicado en 2001

Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes

scientific article published on 06 July 2016

Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas

artículo científico publicado en 2001

Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma

scientific article published on 01 September 2004

Diffuse Large B-Cell Lymphoma Version 1.2016

scientific article published on 01 February 2016

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.

artículo científico publicado en 2015

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.

artículo científico publicado en 2015

Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States

artículo científico publicado en 2016

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

artículo científico publicado en 2019

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

artículo científico publicado en 2015

Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG).

artículo científico publicado en 2017

Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

artículo científico publicado en 2012

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

artículo científico publicado en 2004

Electronic Chemotherapy Order Entry: A Major Cancer Center's Implementation.

artículo científico publicado en 2011

Emerging role of laparoscopy in the diagnosis of lymphoma

scientific article published on 01 May 1998

Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma

artículo científico publicado en 2001

Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials

artículo científico publicado en 2018

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

artículo científico publicado en 2012

Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.

artículo científico publicado en 2015

Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification.

artículo científico publicado en 2011

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma

artículo científico publicado en 2020

FDG-PET lymphoma demonstration project invitational workshop

scientific article published on 01 March 2007

Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma

artículo científico publicado en 1998

False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma

artículo científico publicado en 2013

Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma

artículo científico publicado en 2014

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

scientific article published on 17 April 2019

Follicular lymphoma in the United States: first report of the national LymphoCare study

scientific article published on 09 February 2009

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

artículo científico publicado en 2020

Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Detected by Clonotypic Polymerase Chain Reaction Despite Continuous Pathologic Remission Induced by Involved-Field Radiotherapy

artículo científico publicado en 2005

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

artículo científico publicado en 2007

Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma

artículo científico publicado en 2014

Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

artículo científico publicado en 2016

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

artículo científico publicado en 2018

Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia

artículo científico publicado en 2013

Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

artículo científico publicado en 2014

Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy

artículo científico publicado en 2000

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2017

Hepatitis B virus management to prevent reactivation after chemotherapy: a review.

artículo científico publicado en 2012

High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex

artículo científico publicado en 2016

High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.

artículo científico publicado en 2012

High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging

artículo científico publicado en 2010

High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis

scientific article published on 01 October 2000

Hodgkin disease/lymphoma

scientific article published on 01 July 2008

Hodgkin disease/lymphoma. Clinical practice guidelines in oncology

scientific article published on 01 March 2006

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.

artículo científico publicado en 2019

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2017

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

artículo científico publicado en 1999

Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma

artículo científico publicado en 2003

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial

artículo científico publicado en 2020

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

artículo científico publicado en 2014

Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma

artículo científico publicado en 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

artículo científico publicado en 2012

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

artículo científico publicado en 2018

Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma

artículo científico publicado en 2003

Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience

artículo científico publicado en 2012

Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis

artículo científico publicado en 2003

Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas

artículo científico publicado en 1997

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

artículo científico publicado en 2017

Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity

article

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

scientific article published on 01 February 2024

Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database

artículo científico publicado en 2011

Lessons From ASH 2010: A Focus on NHL

artículo científico publicado el 1 de enero de 2011

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma

artículo científico publicado en 2017

Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab

scientific article published on 01 September 2019

Lymphoid malignancies: a decade and a half of dramatic improvements in outcome

scientific article published on 01 August 2008

MUC-1 mucin protein expression in B-cell lymphomas

scientific article published on 01 March 2003

MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma.

artículo científico publicado en 2000

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

artículo científico publicado en 2007

Marker-controlled watershed for lymphoma segmentation in sequential CT images

artículo científico publicado en 2006

Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region.

artículo científico publicado en 2010

Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression

artículo científico publicado en 2007

Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma

artículo científico

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

artículo científico publicado en 2000

Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells.

artículo científico publicado en 2014

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

artículo científico

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

artículo científico publicado en 2010

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

scientific article published on 01 June 2019

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

artículo científico publicado en 2017

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

artículo científico publicado en 2016

NCCN Roundtable: What Are the Characteristics of an Optimal Clinical Practice Guideline?

artículo científico publicado en 2015

NCCN task force report: molecular markers in leukemias and lymphomas

scientific article published on July 2009

NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.

artículo científico publicado en 2007

Non-Hodgkin's Lymphomas, version 3.2012

artículo científico publicado en 2012

Non-Hodgkin's lymphoma clinical practice guidelines

artículo científico publicado en 2004

Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology

artículo científico publicado en 2006

Non-Hodgkin's lymphomas

artículo científico publicado en 2008

Non-Hodgkin's lymphomas

artículo científico publicado en 2011

Non-Hodgkin's lymphomas, version 1.2013.

artículo científico publicado en 2013

Non-Hodgkin's lymphomas, version 2.2014

artículo científico publicado en 2014

Non-Hodgkin's lymphomas, version 4.2014.

artículo científico publicado en 2014

Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era

artículo científico publicado en 2015

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

artículo científico publicado en 2011

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

artículo científico publicado en 2018

Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.

artículo científico publicado en 2008

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

artículo científico publicado en 2009

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

artículo científico publicado en 2020

Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience

artículo científico publicado en 2020

Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant

artículo científico publicado en 2018

Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era.

artículo científico publicado en 2016

Overview of lymphoma diagnosis and management.

artículo científico publicado en 2008

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

artículo científico publicado en 2015

Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response

artículo científico publicado en 2003

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

artículo científico publicado en 2009

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

artículo científico publicado en 2019

Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes

scientific article published on 25 February 2013

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

artículo científico publicado en 2006

Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation

artículo científico publicado en 2009

Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma

scientific article published on 29 April 2019

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

artículo científico publicado en 2009

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma

artículo científico publicado en 2011

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

artículo científico publicado en 2014

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

artículo científico publicado en 2004

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma

artículo científico publicado en 2012

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

artículo científico publicado en 2009

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

artículo científico publicado en 2001

Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

artículo científico publicado en 2020

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

artículo científico publicado en 2007

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

artículo científico publicado en 2010

Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.

artículo científico publicado en 2005

Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.

artículo científico publicado en 2015

Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial

scientific article published on 13 March 2020

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma

artículo científico publicado en 2010

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

scientific article published on 17 May 2019

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

artículo científico publicado en 2017

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

artículo científico publicado en 2015

Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

scientific article published on 01 October 2003

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

artículo científico publicado en 2009

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

artículo científico publicado en 2004

Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma

artículo científico publicado en 2015

Proteasome inhibitors in non-Hodgkin's lymphoma

artículo científico publicado en 2005

R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy

artículo científico publicado en 2005

Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project

artículo científico publicado en 2014

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

artículo científico publicado en 2015

Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

artículo científico publicado en 2018

Recent advances in the treatment of non-Hodgkin's lymphomas.

artículo científico

Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas

artículo científico publicado en 2003

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

artículo científico publicado en 2004

Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib

artículo científico publicado en 2020

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

scientific article published on 19 October 2018

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma

artículo científico publicado en 2010

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

artículo científico publicado en 2004

Rituximab for Aggressive Non-Hodgkin??s Lymphomas Relapsing After or Refractory to Autologous Stem Cell Transplantation

scientific article published on 01 September 2002

Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.

artículo científico publicado en 2018

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses

artículo científico publicado en 2008

Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma

artículo científico publicado en 2002

Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience

artículo científico publicado en 2010

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.

artículo científico publicado en 2013

Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma

scientific article published on 01 December 2007

Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.

artículo científico publicado en 2006

Surveillance imaging for lymphoma: pros and cons

artículo científico

Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies

scientific journal article

Synchronous presentation of systemic and brain non-Hodgkin lymphoma

artículo científico publicado en 2008

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

artículo científico publicado en 2011

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

artículo científico publicado en 2016

The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma

artículo científico publicado en 1999

The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide

artículo científico publicado en 2004

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

artículo científico publicado en 2017

The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma

artículo científico publicado en 2013

The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months

artículo científico publicado en 2016

The radioisotope contributes significantly to the activity of radioimmunotherapy.

artículo científico publicado en 2004

The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.

artículo científico publicado en 2009

Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

artículo científico publicado en 2020

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

artículo científico publicado en 2010

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas

scientific article published on 26 September 2005

Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

artículo científico publicado en 2013

Treatment of follicular lymphoma: current status

artículo científico publicado en 2008

Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report

artículo científico publicado en 2011

Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy.

artículo científico publicado en 2014

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma

artículo científico publicado en 2020

Vaccination with CD20 peptides induces a biologically active, specific immune response in mice.

artículo científico publicado en 2002

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

scholarly article by Andrew D Zelenetz et al published 2 May 2019 in Blood

[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda